Iovance Biotherapeutics (IOVA) EBT (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly EBT of -$79.7 million for Q1 2026, up 32.45% year-over-year from -$60.2 million in Q1 2025, and down 11.14% quarter-over-quarter from -$71.7 million in Q4 2025.
Iovance Biotherapeutics (IOVA) EBT (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported EBT for 17 consecutive years, with -$79.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT rose 32.45% year-over-year to -$79.7 million; the TTM figure through Mar 2026 stood at -$354.8 million (up 6.3% YoY), while the FY2025 annual figure was -$393.0 million, down 4.81% from the prior year.
- EBT retreated to -$79.7 million in Q1 2026 per IOVA's latest filing, from -$71.7 million in the prior quarter.
- Across five years, EBT topped out at -$71.7 million in Q4 2025 and bottomed at -$119.2 million in Q1 2022.
- Historically, EBT has averaged -$101.1 million across 5 years, with a median of -$105.3 million in 2022.
- Annual changes were most pronounced in 2022 — EBT sank 52.98% — and 2024, when it jumped 34.82%.
- Iovance Biotherapeutics' EBT stood at -$105.3 million in 2022, then retreated by 12.17% to -$118.1 million in 2023, then surged by 34.82% to -$77.0 million in 2024, then climbed by 6.86% to -$71.7 million in 2025, then decreased by 11.14% to -$79.7 million in 2026.
- Business Quant data shows IOVA's EBT at -$79.7 million in Q1 2026, -$71.7 million in Q4 2025, and -$93.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -48.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.69 Mn |
| Mar 31, 2026 | -79.71 Mn |
| Dec 31, 2025 | -71.72 Mn |
| Sep 30, 2025 | -93.66 Mn |
| Jun 30, 2025 | -109.67 Mn |
| Mar 31, 2025 | -118.00 Mn |
| Dec 31, 2024 | -77.00 Mn |
| Sep 30, 2024 | -85.06 Mn |
| Jun 30, 2024 | -98.56 Mn |
| Mar 31, 2024 | -114.38 Mn |
| Dec 31, 2023 | -118.14 Mn |
| Sep 30, 2023 | -115.00 Mn |
| Jun 30, 2023 | -107.01 Mn |
| Mar 31, 2023 | -107.37 Mn |
| Dec 31, 2022 | -105.32 Mn |
| Sep 30, 2022 | -99.62 Mn |
| Jun 30, 2022 | -99.35 Mn |
| Mar 31, 2022 | -119.19 Mn |
| Dec 31, 2021 | -93.09 Mn |
| Sep 30, 2021 | -89.73 Mn |